112779-14-3

Basic information

• Product Name: ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE
• Synonyms: ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE;-1H-pyrazole-4-carboxylate;Ethyl 5-amino-1-(tert-butyl);BUTTPARK 87\09-30
• CAS NO: 112779-14-3
• Molecular Formula: C₁₀H₁₇N₃O₂
• Molecular Weight: 211.26
• Mol File: 112779-14-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 324.484 °C at 760 mmHg
• Flash Point: 150.043 °C
• Appearance: /
• Density: 1.154 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.09±0.10(Predicted)
• CAS DataBase Reference: ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE(112779-14-3)
• EPA Substance Registry System: ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE(112779-14-3)

Safety Data

• Hazardous Substances Data: 112779-14-3(Hazardous Substances Data)

Usage

General Description

ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE is a chemical compound with the molecular formula C11H18N4O2. It is a derivative of pyrazole with a carboxylate functional group and is commonly used in organic synthesis and pharmaceutical research. ETHYL 5-AMINO-1-TERT-BUTYLPYRAZOLE-4-CARBOXYLATE is often utilized in the development of new drugs and is known for its potential pharmacological properties. Its unique structure and functional groups make it a valuable building block for the synthesis of various bioactive compounds and pharmaceutical ingredients. Additionally, it has attracted interest in the field of medicinal chemistry due to its potential applications in the treatment of various diseases and medical conditions.

Upstream product

• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 7400-27-3 tertbutylhydrazine hydrochloride 
• 3530-11-8 butylhydrazine 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 
• 72459-84-8 ethyl (ethoxymethylene)cyanoacetate 

Downstream Products

• 1421847-33-7 2-{2-[1-tert-butyl-5-(4-methoxyphenyl)-1H-pyrazol-4-yl]-1,3-thiazol-4-yl}-N-(tetrahydro-2H-pyran-4-ylmethyl)acetamide 
• 1421847-35-9 2-[2-(1-tert-butyl-5-phenyl-1H-pyrazol-4-yl)-1,3-thiazol-4-yl]-N-(tetrahydro-2H-pyran-4-ylmethyl)acetamide 
• 1421847-37-1 2-{2-[1-tert-butyl-5-(4-cyanophenyl)-1H-pyrazol-4-yl]-1,3-thiazol-4-yl}-N-(tetrahydro-2H-pyran-4-ylmethyl)acetamide 
• 1421849-47-9 (E)-1-tert-butyl-5-(4-methoxystyryl)-1H-pyrazole-4-carboxamide 
• 1421849-48-0 1-tert-butyl-5-(4-methoxyphenethyl)-1H-pyrazole-4-carboxamide 
• 1421848-26-1 2-{2-[1-tert-butyl-5-(4-chlorophenyl)-1H-pyrazol-4-yl]-1,3-thiazol-4-yl}-N-(tetrahydro-2H-pyran-4-ylmethyl)acetamide 
• 1374257-85-8 4-((5-bromo-1-tert-butyl-1H-pyrazol-4-yl)methyl)-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 
• 1245272-40-5 ethyl 5-bromo-1-tert-butyl-1H-pyrazole-4-carboxylate 
• 112779-13-2 ethyl 1-tert-butyl-5-chloro-1H-pyrazole-4-carboxylate 

Relevant articles and documents

1-tert-butyl-5-amino-4-pyrazol-1, 3, 4-oxadiazole thioether compounds and application thereof

The invention discloses 1-tert-butyl-5-amino-4-pyrazol-1, 3, 4-oxadiazole thioether compounds. The compounds are characterized in that the structural formula of the 1-tert-butyl-5-amino-4-pyrazol-1, 3, 4-oxadiazole thioether compounds is shown in the specification, and R1 in the formula is an alkyl group, a phenyl group or a substituted phenyl group. On the basis of the structure of the 1-phenyl-5-amino-4-pyrazole bisoxadiazole thioether, a series of 1-tert-butyl-5-amino-4-pyrazolyl-1, 3, 4-oxadiazole oxadiazole thioether compounds are synthesized by taking pyrazol as a raw material and replacing the phenyl group on the 1-position of a pyrazol ring with tert-butyl, and the compounds have good treatment, protection and passivation activity on virus diseases caused by tobacco mosaic virus (TMV) through in-vivo experiments of the compounds. And compared with other compounds of the same kind, the compounds of the invention have better protective activity.

HETEROCYCLIC COMPOUND

Provided is a heterocyclic compound having an RORγt inhibitory activity. A compound represented by the formula (I): wherein ring A is an optionally substituted cyclic group, Q is a bond, optionally substituted C1-10 alkylene, optionally substituted C2-10 alkenylene, or optionally substituted C2-10 alkynylene, R1 is a substituent, ring B is a thiazole ring, an isothiazole ring or a dihydrothiazole ring, each of which is optionally further substituted by a substituent in addition to R2, and R2 is an optionally substituted cyclyl-carbonyl-C1-6 alkyl group, an optionally substituted aminocarbonyl-C1-6 alkyl group, an optionally substituted cyclyl-C1-6 alkyl group, an optionally substituted cyclyl-C1-6 alkylamino-carbonyl group, an optionally substituted aminocarbonyl-C2-6 alkenyl group, an optionally substituted C1-6 alkylcarbonylamino-C1-6 alkyl group, an optionally substituted cyclyl-aminocarbonyl group, an optionally substituted cyclyl-carbonyl group or an optionally substituted non-aromatic heterocyclic group, or a salt thereof.

Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.